ADCY5 and movement disorder: The cases that are less responsive to therapy among those described in our systematic review involving the ADCY5 gene are, for example, those described by Quazza and colleagues [45], who describe movement disorders associated with the onset of static cervical dystonia; they seem to benefit most from methylphenidate therapy (0.6 mg/kg/day) in one case (PKD, PNKD and nocturnal episodes) and in one case with spontaneous resolution once they reach adulthood (PHD).